Eli Lilly continues to dominate the obesity market with Zepbound and Orforglipron, leading JPMorgan to see it as a top pick ...

A survey by PSG has found that the pressure to control drug costs is leading some payers to look into unbundling pharmacy ...

Hims & Hers Health is betting that the cash-pay market for weight-loss drugs will drive up customer demand although some ...

“With the semaglutide shortage declared over, Hims now has to transition its model to generate growth from other products ...

Some Blue Cross and Blue Shield insurers dipped their toes into expanding coverage for blockbuster weight-loss drugs, then ...

Fifteen Connecticut companies made the 2025 Fortune 500 list of the largest U.S. corporations, which was announced Monday-- a sign of stability in the state's corporate sector. Bloomfield- ...

While employers aren’t yet reimbursing weight loss drugs en masse, significantly reduced net costs could affect their future ...

CVS Pharmacy plans to close 271 retail locations this year, according to the company’s fourth-quarter report on 2024 earnings. The move, according to the report, is part of a “continuous ...

A new clinical trial has revealed that tirzepatide (Zepbound) surpasses semaglutide (Wegovy) in promoting weight loss among people with obesity. A new clinical trial has found that tirzepatide, sold ...

Donation Options Search Search Search Boxes of the weight-loss medications Wegovy and Zepbound. JoNel Aleccia / AP Share Excess body weight can raise the risk of certain cancers. So researchers ...

CVS CAREMARK IS A PHARMACY BENEFITS MANAGER, OWNED BY CVS HEALTH, WHICH OWNS AND OPERATES CVS PHARMACIES. "I want to be clear. House Bill 1150 does not force pharmacy closures. It forces companies ...

Over the past few years, demand for blockbuster medications like Ozempic, Wegovy and Zepbound skyrocketed. These drugs are typically prescribed to address a range of health issues, including ...